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The impact of socioeconomic status on access
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Cancer clinical trials enable the development of novel agents for the potential benefit of cancer patients. Enrolment in a trial offers
patients the chance of superior efficacy coupled to the risk of unanticipated toxicity. For trial results to be generalisable, the data
need to be collected in patients’ representative of the general cancer population. Socioeconomic deprivation is associated with
poor cancer outcomes. In the developed world, the gap between the most and least deprived is widening. This mini-review
explores the evidence regarding socioeconomics and access to cancer trials, highlighting the underrepresentation of deprived
patients, and exploring reasons for this disparity.
Although worldwide life expectancy is improving, the gap in life
expectancy between the most and least affluent is widening in the
developed world (Thomas et al, 2010; Krieger et al, 2012). This
separation may largely be driven by the health impact of high-risk
lifestyle activities such as smoking, poor diet and inactivity, which
vary in prevalence by socioeconomic status (SES). However,
differential access to care, especially in countries where universal
health care is not the norm, may also be a dominant factor in SES-
related life expectancy disparities (Disparities in cancer care, 2006).
Cancer care is similarly subject to the same SES-related health
disparity factors (2006). The burden of cancer care on lower SES
populations is increased, they are less likely to attend cancer
screening programmes, and suffer from poorer outcomes (2006;
Renshaw et al, 2010; Herndon et al, 2013). As interventional
clinical research is integral to much of modern cancer care, in this
review we explore ways in which access to cancer clinical trials
(CCTs) may be influenced by common health and sociodemo-
graphic inequalities.
While the exposure of patients to effective novel treatments is a
benefit of clinical trials, this must be balanced against the fact that
in randomised studies patients may experience greater incon-
veniences (trips, tests, etc.) simply to acquire the standard of care
and many studies of agents show either no benefit or worsened
outcomes compared with standard of care therapies. Of note, the
level of negative clinical research outcomes may be underestimated
in practice due to publication bias in favour of CCTs reporting
positive outcomes (Tam et al, 2011). However, evidence supports
RCTs offering at least equivalence to standard treatment
(Gross et al, 2006), and enrolment of patients in CCTs is
considered by physicians to be of value and importance (Somkin
et al, 2005). If we accept the premise that CCTs are overall of
benefit to patients and the advancement of cancer care, then they
should, in theory, be offered to all eligible patients for reasons of
equity. In addition, for CCTs to deliver conclusions that are
applicable in practice they should be drawn from populations for
whom the treatment is intended. In an ideal world the mix of
patients in clinical trials should reflect the mix of patients receiving
treatment for cancer in general.
EVIDENCE OF UNEQUAL ACCESS TO CLINICAL TRIALS
IN RELATION TO SES
In the United States recognition of disparities in clinical trial access
has lead to national policy strategies. In 1993, the National
Institutes of Health (NIH) passed the ‘Revitalization Act’ stating
that women and minorities must be better represented in clinical
research. In keeping with this, the Federal Drug Administration
(FDA) began mandating gender analysis in clinical trial data and
reversed its requirement that women of childbearing age be
excluded from early phase trials. Between 1993 and 2002, the
budget of the National Cancer Institute (NCI) doubled, with an
associated significant rise in NCI CCT accrual to 2.5% (Shavers
and Brown, 2002). In the United Kingdom, the creation of the
National Cancer Research Network (NCRN) has seen recruitment
to cancer research studies rise from 3.7% to 17% of newly
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diagnosed cancer patients between 2001 and 2011. Despite this
progress, minorities, the elderly, adolescents, patients from rural
communities, and (in regions without universal health care) the
uninsured remain underrepresented (Kwiatkowski et al, 2013).
With regard to SES, Sateren et al (2002) examined the accrual of
patients to NCI-sponsored clinical trials over a 1-year period. They
found that higher socioeconomic levels were associated with an
increased accrual to clinical trials. Associated factors included:
income (increase of 0.7 patients per $1000 increase in mean
income); poverty (decrease of 0.32 patients per 1% increase in
population in poverty); education level (increase of 1.51 patients
per 1% increase in population with a college degree); and
employment (decrease of 0.7 patients per 1% increase in
unemployment). They also noted that patients enrolled onto
clinical trials were less likely to be uninsured, and more likely to
have Medicare (in 2000 Medicare policy was changed to cover the
routine costs of trial participation). Data from Maryland between
1999 and 2002 revealed lower accrual to trials with increasing
deprivation scores. Those enrolled were less likely to be uninsured,
or covered by Medicaid or private insurance, compared with the
general population. Recruitment was found to be associated with
social class (Baquet et al, 2008).
Income was also notably associated with trial participation in an
internet-based survey of 5499 patients asked about their cancer
treatment decisions (Unger et al, 2013). Among the survey
respondents, both discussion of a trial and subsequent participa-
tion were associated with being younger, wealthier, and more
highly educated.
Both education attainment and wealth estimates are most
commonly used in models of SES. Education alone is also
considered as a valid surrogate of SES (Herndon et al, 2013).
In a survival analysis of 6166 breast cancer patients enrolled in
clinical trials conducted between 1987 and 2003 by the Cancer and
Leukemia Group B collaborative research group, only 12% of those
enrolled onto trials did not have a high school diploma, in
comparison with 31% nationally (Alliance for Excellent Education,
2009) suggesting significant underrepresentation of patients with
lower educational levels in these trials. In addition, even among
those enrolled on trials lower educational attainment was
associated with poorer outcomes (Herndon et al, 2013).
In the setting of early phase cancer trials there is evidence that
referral is biased significantly in favour of the more affluent
population, with enrolment on a trial after contact with the trials
clinic not affected by SES (Mohd Noor et al, 2013). In another
US-based study, patients of moderate-to-high SES were over-
represented. Only 5% had not graduated from high school (cf 31%
nationally), and 24% had postgraduate degrees. In all, 11% had a
household income of less than $25 000 in comparison with a figure
of 25% nationally in 2011 (US Department of Commerce, 2011).
SOCIOECONOMIC REASONS FOR LOW RECRUITMENT
Patient factors. Lack of education about cancer and CCTs is a
frequently reported barrier to trials access (Mills et al, 2006; Ford
et al, 2008). Less readily defined are aspects of culture and belief
that influence patient decision-making. When considering under-
representation of African Americans (AAs) in CCTs the impact of
the Tuskegee syphilis study on trust in medical research is often
cited (Corbie-Smith, 1999). It is notable that this may lead to
assumptions about willingness to participate, exacerbating recruit-
ment bias. Therefore, it is important to note that surveys of cancer
patients in regions of the United States do report equal willingness
to participate in CCTs among AAs, Hispanics, and whites, despite
a greater reported fear of participation in randomised trials (Byrne
et al, 2013). A synthesis of the available literature on AA patients’
participation in cancer prevention, screening, and intervention
trials found five elements key to CCT participation: negative beliefs
about trials, lack of knowledge, influence of faith, health-care
provider influence, and friends’ or relatives’ participation in CCTs,
or recommendations (Rivers et al, 2013). Addressing these
complex social barriers likely requires tailored community
engagement. The use of ethnicity as a variable to examine
underrepresentation of other groups of patients in CCTs is
emerging as an oversimplification. There is growing evidence that
outcome differences attributed to race may in fact be more
dependent on SES (Du et al, 2008), with SES a key barrier to
enrolment (Sateren et al, 2002). Consideration of both race and
SES when addressing inequality enables clearer delineation of true
barriers within communities.
Many CCTs mandate a certain level of global fitness, as well as
standard measures for organ function. Multiple co-morbidities
associated with poor pre-cancer health may negatively impact on a
patient’s ability to meet these protocol mandated criteria.
Education level, as a surrogate of SES, has been shown to inversely
correlate with leading causes of death, and as noted in the CALGB
trial with worsened outcomes within clinical trials (Jemal et al,
2008). These eligibility criteria barriers are a frequently cited cause
of non-participation for underrepresented populations in CTCs
(Mills et al, 2006; Ford et al, 2008). It has been reported that people
from lower socioeconomic groups are less likely to attend for
cancer screening programmes, and present at later stages of disease
(Ionescu et al, 1998; Renshaw et al, 2010). Certainly, late
presentation, and late initial therapy, could increase the risk of
co-morbidity hindering recruitment to trials.
The information offered about clinical trials may be in an
inappropriate form for many except those patients with high
educational attainment. The language used in patient information
and consent forms has long been a concern: a study in 2003 found
that consent forms consistently failed readability guidelines, with
language complexity hindering understanding for people with low
reading levels (Paasche-Orlow et al, 2003). This inevitably affects
those with lower educational attainment disproportionately, and
may result in refusal to participate in trials. In areas or groups in
which minority languages are commonly spoken, with the
assumption that these may be more associated with lower SES,
ease and speed of access to translators and to either long or short
form translated consent forms may be an additional factor
influencing relevant communication about clinical trials.
Financial concerns are of relevance even in areas with universal
health care such as the United Kingdom. Hidden costs, such as
travel to and from clinics, the need for extra childcare, and the loss
of income due to missed work will be more significant for those of
lower SES. These costs are compounded in areas with no universal
health-care provision by concerns about insurance coverage of
participation in clinical trials, or indeed about whether any care is
available where the patient is uninsured. In the United States,
indigent insurance programmes may restrict care to specific
hospitals in the region, which may not be the same hospitals with
thriving clinical research programmes. Indeed, in the United States
and many countries, clinical trials are not universally distributed
across geographic areas. For example, US national level for lung
cancer patient enrolment in clinical trials is B3%, but in some
NCI-designated cancer centres accrual rates, which are highly
clustered in key urban populations, may reach ten times this value.
More affluent populations may be more likely to seek out
physicians at centres with clinical trial portfolios. While patients
with good insurance may choose to travel they still need accurate
information on where specific novel therapies may be available
(West and Camidge, 2012). National trials registry sites such as
www.clinicaltrials.gov do exist, but their ease of use is questionable
for those with lower educational levels. Financial coercion via
compensation for trial participation may disproportionately affect
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poorer patients—if you are wealthy being paid to participate is not
an incentive—for this reason inclusion of financial incentives in
CTCs is rarely considered as ethical.
Health-care professional factors. To be initially referred for
consideration of a trial, the referring clinician must consider the
patient a candidate. There are several reasons why they may not do so.
First, as mentioned above, the patient may suffer from multiple
comorbidities, which the clinician seen as incompatible with
clinical trial involvement. Second, the clinician may be unaware of
a trial that is applicable for the patient, so that trial access becomes
dependent upon the patient’s motivation and access to informa-
tion. Third, the clinician may make decisions, either consciously or
sub-consciously, about the appropriateness of referral for a trial
based on assumptions about their socioeconomic characteristics.
Physicians in specialist centres are more orientated towards
research than those based in community general hospitals (Ford
et al, 2011). Physicians are more likely to refer patients for CCTs
than surgeons (Klabunde et al, 2011). In early phase CCTs, SES has
been shown to be a clear barrier to referral (Mohd Noor et al,
2013). In addition, it is of concern that clinicians’ preconceptions
about patients’ willingness or ability to participate may be a
contributing factor. A cancer patient’s initial treating specialist,
surgeon or physician, therefore, has a very important and
influential role in their care. A lack of understanding of CCTs,
or a wariness about trials on the clinician’s part has the potential to
impact significantly on referral, but also on patient attitudes to trial
enrolment (Mills et al, 2006). Education about trials in general and
available CCTs in particular is key to overcoming referrer bias, as is
a focus on communication skills for front-line clinicians. (Ford
et al, 2011). More directed strategies to overcome referrer barriers
to CCT access are complex, and in practice prove difficult to
deliver (Michaels et al, 2012). A final clinician-driven obstacle to
enrolment is the complex nature of CCTs. A clinician may not
have time to provide adequate explanation and counseling about
the trial, particularly in for-profit private practice models in some
countries. Given these time constraints, often it may simply be
‘easier’ for the clinician to only counsel more educated patients
about trials.
SOLUTIONS TO THE PROBLEM
Improving the access of patients from lower socioeconomic groups
to cancer screening, diagnosis and therapy will increase their
representation on clinical trials. General health-care policy such as
national smoking cessation programmes and alcohol awareness
campaigns will go some way to decrease the levels of comorbidities
disproportionally affecting lower socioeconomic groups. These are,
however, long-term national strategies not influenced by clinical
trial stakeholders. Improving the recruitment from the current
pool may be affected through improved communication, both
between health-care professional and patient, and from clinical
trial investigators to referring physicians.
Social and cultural barriers can and have been addressed by
innovative approaches; prostate cancer screening information in
AA barber shops, flexible timing of screening interventions for
busy working mothers and educating clergy to address barriers to
cancer care to name but a few (Sadler et al, 2001; Hart et al, 2008;
Germino et al, 2011). These approaches are labour intensive,
potentially costly and may only access small populations, however,
multiple small solutions to this large problem could be the way
change is affected.
It is important that all patients are considered for clinical trial
enrolment, and that any exclusion from recruitment is based upon
trial entry criteria. To that end referring clinicians should be made
aware of all potential trials available. Proactive strategies to
encourage referral of patients from lower SES groups may be of
benefit, but are challenging to implement (Michaels et al, 2012).
For patients with low reading levels, a video presentation rather
than written material may be useful (Unger et al, 2013). Improved
readability of leaflets with simple language may help in conveying
complex concepts to all patients regardless of education level. From
2014, all insurance providers in United States will be obliged to
cover standard costs of clinical trials. This step will hopefully make
CCTs more desirable to US cancer patients. Where the cost of
travel is a limitation, satellite clinics closer to patients’ homes, as
well as expanding portfolios of trials in rural practice settings away
from large cancer centres, may improve access for more deprived
populations.
Finding methods to engage minority groups with cultural
sensitivity is key to helping reduce the impact of pre-conceptions
among underprivileged groups regarding safety and applicability of
CCTs (Germino et al, 2011). The use of patient navigators with
training in cultural barriers prevalent in the communities they
serve may help overcome some of the patient-derived obstacles to
CCT enrolment.
Finally, health-care professionals must address their own
communication abilities. Full and clear communication is better
for patients. Infrastructure needs to be in place to ensure discussion
of CCTs is possible within the clinical framework, to better
improve communication between patients and staff. Trust is a key
in care delivery, all the more so when considering enrolment in a
trial.
CONCLUSIONS
Under representation of lower SES groups in cancer trials is a
pressing issue for cancer researchers. Improving CCT access for
these groups has been a key policy issue internationally for some
time. There is a large literature on barriers to CCTs, and on
strategies to improve accrual. Organisational approaches to
improve CCT access have begun to produce results, but largely
just in total numbers recruited to trials, with little impact seen on
inequalities. There is still some way to go before the benefits and
burdens of CCTs are born by truly representative patient
populations.
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